Recon: Drugmakers counter Trump's pricing plan; Teva indicted by US DOJ on price-fixing charges

• Drugmakers deliver counteroffer to Trump international pricing plan (Politico)
• Does Purdue’s Reformulated OxyContin ER Really Deter Abuse? US FDA Panel To Decide (Pink Sheet)
• Eric Topol Criticizes FDA's Exaggeration Of Plasma's Efficacy In COVID-19 Treatment (NPR)
• Trump Again Claims He’s Bringing Down Drug Prices, But Details of How Are Skimpy (KHN)
• Opinion: The FDA must stand up for itself and for science, not politics (Washington Post)
• Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout (Xconomy)
• Ipsen Plans to Move Forward with Filing for FOP Drug (Global Genes)
• Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial (Fierce Biotech)

• 73,000 Scientists collaborate over new COVID-19 Data Portal to speed up vaccine development (PharmaNews)
• COVID-19 vaccine deals with the EU hindered by strict liability rules (PMLive)
• Kura hires Tagrisso lead to take cancer drugs deeper into clinic (Fierce Biotech)
• Bavarian Nordic’s freeze-dried smallpox vaccine clears clinical test (BioPharma Reporter)
• Amid deepening desperation, the story of those who won't wait for superpowers’ Covid vaccines (Economic Times)
• Russia seeks collaboration with India for manufacturing Covid vaccine Sputnik V: Report (Economic Times)

• CDC says asymptomatic people don't need testing, draws criticism from experts (NYT) (The Hill) (CNBC) (NBC)
• When FDA Might Approve A Coronavirus Vaccine (NPR)
• Moderna's COVID-19 vaccine shows similar immune response in old and young (Reuters) (Moderna)
• Convalescent Plasma: The Unanswered Questions (MedPage Today)
• Biogen conference likely linked to 'tens of thousands' of COVID-19 cases, researchers say (Fierce Pharma) (MedCity News)
• EU eyes initial COVID-19 vaccination for at least 40% of population (Reuters)
• Trump Administration Orders Hospitals to Report Data or Risk Losing Funding (NYT)
• Can China Convince World With Its Fast, Cheap COVID Vaccines? (Pink Sheet)
• Thousands of coronavirus cases recorded in hospital were caught on site, new research suggests (Pharmafile)
• Dr. Scott Gottlieb: ‘This is really a 2020 event’ provided U.S. stays vigilant on coronavirus (CNBC)
• Inside Pence's coronavirus task force (Politico)
• Coronavirus (COVID-19) Update: Daily Roundup August 25, 2020 (FDA)
• COVID-19 exposes a critical shortage of oxygen in developing countries (McKinsey)

• Catalyst takes its fight over a rare disease drug to Canada, suing the country’s regulator (STAT)
• Bristol/Agios AML Drug Idhifa Fails In Phase III (Scrip)
• Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say (Pink Sheet)
• New CF Patient Subset For Vertex With Kaftrio's EU Approval (Scrip) (European Pharmaceutical Review)
• Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS (Scrip) (BioPharma Dive)
• Strengthening the sting of immunotherapy (Nature)
• Thread Research lands $50m infusion for decentralized trial tech (Outsourcing-Pharma.com)
• AbbVie Exercises Option to License Morphic’s Program for IPF and Other Fibrotic Diseases (Global Genes)

• As Elon Musk’s Neuralink prepares to draw back the curtain, ex-employees describe rushed timelines clashing with science’s slow pace (STAT)
• Fitbit launches smartwatch as EKG feature awaits FDA's OK (MedTech Dive)
• Measuring the sensitivity of COVID tests with new material from NIST (AAAS)
• Freenome raises $270M to run pivotal trial of colorectal cancer liquid biopsy (MedTech Dive)
• Insulin pumps among millions of devices facing risk from newly disclosed cyber vulnerability, IBM says (MedTech Dive)
• Covid-19 Is Fueling A Digital Therapeutics Revolution, But The Road To Maturity Travels Through The Four Healthcare ‘Ps’ (Forbes)

• Teva Pharmaceutical’s U.S. Unit Indicted on Price-Fixing Charges (WSJ) (Forbes) (Fox Business)
• 2 Become 1: MAPP on Consolidation of ANDAs (FDA Law Blog)
• Senate bill would give FDA authority to recall drugs (Law 360)
• Sequence Comparisons Illustrate Susceptibility to Coronavirus Infection (Patent Docs)
• FDA and Lab-Developed Tests: The Saga Continues (MedPage Today)